Support is requested for a Keystone Symposia conference entitled Emerging Cell Therapies: Realizing the Vision of NextGen Smart Cell Therapeutics for Disease organized by Drs. Kole T. Roybal, Alex Marson and Yvonne Y. Chen. The conference will be held in Keystone, Colorado from January 24-28, 2021. Cellular therapeutics are poised to be a next pillar of medicine along with small molecules and biologics. These living drugs have a unique capacity for more complex decision-making and therapeutic responses, potentially alleviating the need for chronic treatment. Next-generation cell therapies will need to adapt and respond to disease progression, essentially functioning as microscopic ?physicians? capable of sensing, diagnosing, and eradicating disease via multifaceted mechanisms that are difficult to resist yet similar to our natural immune system. Advances in engineered T cell therapeutics are being FDA approved and are now transforming treatment plans for cancers that previously had few therapeutic options. While there have been unprecedented complete responses in a subset of hematological malignancies, the current therapies can show significant toxicity and on the other hand show a lack of efficacy in solid tumors. Beyond cancer, engineered cell therapies could have significant impact in the treatment of autoimmunity, metabolic disorders and in regenerative medicine. This conference will therefore cover next-generation cellular engineering approaches designed to tackle refractory diseases such as solid tumors, while also addressing the higher safety requirements for diseases beyond late-stage metastatic cancers. This conference brings together clinically minded cell therapists, synthetic biologists, genome and protein engineers, systems biologists, and immunologists; this combined expertise is essential to establish cells as a safe and effective therapeutic strategy across a range of diseases. Smart cellular therapeutics of the future must be easily customizable, have intrinsic control systems to prevent toxicity, and be able to overcome rapidly evolving mechanisms preventing disease resolution; this conference aims to address these topics by convening global experts across a range of relevant disciplines.

Public Health Relevance

Cellular therapeutics are living drugs that have a unique capacity for more complex decision-making and therapeutic responses, potentially alleviating the need for chronic treatment, positioning them to be a next pillar of medicine along with small molecules and biologics. This conference is dedicated to understanding the current limitations of cell therapy and the tools that can be brought to bear to circumvent roadblocks preventing therapeutic efficacy in settings such as solid tumors. This conference will integrate approaches across disciplines, creating a unified vision for effective cellular therapeutics, especially for diseases that cannot currently be cured by small molecule drugs or biologics.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Conference (R13)
Project #
1R13CA254054-01
Application #
10070916
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Hunter, Laura
Project Start
2021-01-01
Project End
2021-12-31
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
1
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Keystone Symposia
Department
Type
DUNS #
079780750
City
Silverthorne
State
CO
Country
United States
Zip Code
80498